Aarti Pharmalabs Ltd
AARTIPHARM
Company Profile
Business description
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
Contact
Mulund Goregaon Link Road
204, 2nd Floor, Udyog Kshetra
Mulund West
MumbaiMH400080
INDT: +91 2269436100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
3,005
Stocks News & Analysis
stocks
Avoid this overvalued ASX healthcare share
Expensive healthcare share limited by its core addressable market.
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,857.00 | 48.10 | 0.55% |
| CAC 40 | 8,203.28 | 0.15 | -0.00% |
| DAX 40 | 24,332.99 | 100.07 | -0.41% |
| Dow JONES (US) | 50,665.66 | 206.45 | -0.41% |
| FTSE 100 | 10,240.42 | 13.09 | 0.13% |
| HKSE | 24,407.96 | 157.94 | -0.64% |
| NASDAQ | 25,590.82 | 88.00 | -0.34% |
| Nikkei 225 | 64,179.27 | 1,237.36 | -1.89% |
| NZX 50 Index | 13,253.65 | 49.57 | 0.38% |
| S&P 500 | 7,369.66 | 16.99 | -0.23% |
| S&P/ASX 200 | 8,653.30 | 61.90 | 0.72% |
| SSE Composite Index | 3,993.23 | 16.80 | -0.42% |